Eloralintide (LY3841136) is an investigational long-acting peptide that selectively activates the amylin receptor, the satiety pathway used by the pancreatic hormone amylin.
Amounts reported for Eloralintide are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Human study rows are described per source under Reported protocols; they belong to their trial populations and are not a general amount.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 4 clinical and 2 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical4 rows | |||||
| Phase 2 randomized placebo-controlled trial (48 weeks)263 adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes (mean weight 109.1 kg, BMI 39.1, 78% women), at 46 US sites | 1 mg, 3 mg, 6 mg or 9 mg fixed; or escalation from 6 to 9 mg, or from 3 through 6 to 9 mg | Once weekly | Subcutaneous injection | 48 weeksNot applicable | The Lancet (PubMed)2025 |
| Mean weight change was 9% (1 mg), 12% (3 mg), 18% (6 mg), 20% (9 mg), 20% (6 to 9 mg) and 16% (3 to 9 mg) versus 0.4% on placebo. Nausea was the most common adverse event and tracked the starting dose: 11% at 1 mg, 13% at 3 mg, 64% at a fixed 6 mg, 33% at 9 mg, 54% in the 6 to 9 mg arm and 25% in the slow 3 to 9 mg escalation, against 14% on placebo; fatigue followed a similar pattern. The trial was funded by the manufacturer and several authors are company employees. | |||||
| Phase 2 trial registration with escalation schedules (NCT06230523)Same 263 participants, randomized 2:1:1:1:2:1:2 to placebo and the six active arms | 6 mg for 20 weeks then 9 mg for 28 weeks; or 3 mg for 4 weeks, 6 mg for 4 weeks, then 9 mg for 40 weeks | Once weekly | Subcutaneous injection | 48 weeks of treatment within a study of about 64 weeks including follow-upNot applicable | ClinicalTrials.gov2025 |
| The registry record spells out the two escalation arms that the paper abbreviates, which is the detail most relevant to anyone reading the tolerability data: the gentler schedule spent only 4 weeks at each of 3 mg and 6 mg before reaching 9 mg. Participants were excluded for diabetes, pancreatitis history, bradyarrhythmia and recent cardiovascular events. | |||||
| Phase 1 multiple ascending dose study (12 weeks)100 adults with obesity or overweight (mean age 44, BMI 32.6, 29% women) at three US centers | Five ascending once-weekly dose levels given without escalation; the abstract names a 6 mg cohort but does not list every level | Once weekly | Subcutaneous | 12 weeksNot applicable | Diabetes, Obesity and Metabolism (PubMed)2026 |
| Weight fell 2.6% to 11.3% across dose groups by week 12 with dose-proportional exposure. The most common adverse events were decreased appetite (19%), headache (12%) and fatigue (11%); diarrhea (10%), nausea (8%) and vomiting (4%) were described as infrequent. All authors are employees of the manufacturer. | |||||
| Sponsor press release on the Phase 2 resultsThe 263-participant Phase 2 population | 1 mg, 3 mg, 6 mg, 9 mg, 6/9 mg or 3/6/9 mg | Once weekly | Subcutaneous | 48 weeksNot applicable | Manufacturer investor release2025 |
| The sponsor's release converts the percentages into kilograms from a 109.1 kg average baseline: 10.2 kg at 1 mg up to 21.3 kg at 9 mg. It states that gastrointestinal effects and fatigue were mostly mild to moderate, were lower with slower escalation and matched placebo in the 1 mg and 3 mg arms, and announces Phase 3 monotherapy trials plus a separate Phase 2 study combining eloralintide with tirzepatide in people with type 2 diabetes. | |||||
| Community-reported2 rows | |||||
| Community dosing summary | 1-9 mg, restating the trial range | Once weekly on a consistent day | Subcutaneous; the page notes trials used pre-filled devices and that no reconstitution protocol exists | Not established outside the 48-week trialNot described | Community resource2026 |
| This 2026 wiki page is unusually candid for a community source: it states that eloralintide is investigational, available only through the sponsor's Phase 3 program, and not for purchase or self-administration, and that the optimal escalation schedule has not been disclosed. Its community section reports that forum discussion is anticipation and comparison with GLP-1 drugs rather than use reports. | |||||
| Research-vendor listing (format only) | 10 mg per lyophilized vial; a third-party assay measured 10.39 mg at 99.98% purity | Not stated | Not stated; sold for laboratory research only | Not statedNot stated | Community resource2026 |
| This is a vendor page, not a protocol. It confirms that grey-market eloralintide exists as a 10 mg vial while the drug is still in Phase 3, and lists the same Phase 1, discovery and Lancet papers cited here. The page gives no dosing information. | |||||
The slow-escalation arm of the Phase 2 trial started at 3 mg once weekly, the dose at which nausea (13%) was close to placebo (14%).
The dose stepped up to 6 mg once weekly for 4 weeks. Starting directly at a fixed 6 mg, by contrast, produced nausea in 64% of that arm.
The remaining 40 weeks ran at 9 mg once weekly, ending with 16% mean weight loss, against 20% in the arm that stayed on 6 mg for 20 weeks before moving to 9 mg and 20% on a fixed 9 mg from the start.
Plus 2 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Eloralintide (LY3841136) is an investigational long-acting peptide that selectively activates the amylin receptor, the satiety pathway used by the pancreatic hormone amylin that is released alongside insulin after meals. The sponsor dosed it once weekly by subcutaneous injection in a 48-week Phase 2 trial published in The Lancet in November 2025, where fixed doses of 1-9 mg produced 9-20% weight loss against 0.4% with placebo, and Phase 3 trials are under way. It is not approved anywhere and has never been sold as a medicine; PubChem carries a record for it with no defined stereochemistry and no published full sequence, and research vendors sell it as a 10 mg lyophilized vial.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Energy balance, body composition and incretin signaling.
Mean weight change was 9% (1 mg), 12% (3 mg), 18% (6 mg), 20% (9 mg), 20% (6 to 9 mg) and 16% (3 to 9 mg) versus 0.4% on placebo. Nausea was the most common adverse event and tracked the starting dose: 11% at 1 mg, 13%.
The registry record spells out the two escalation arms that the paper abbreviates, which is the detail most relevant to anyone reading the tolerability data: the gentler schedule spent only 4 weeks at each of 3 mg and.
Weight fell 2.6% to 11.3% across dose groups by week 12 with dose-proportional exposure. The most common adverse events were decreased appetite (19%), headache (12%) and fatigue (11%); diarrhea (10%), nausea (8%) and.
The sponsor's release converts the percentages into kilograms from a 109.1 kg average baseline: 10.2 kg at 1 mg up to 21.3 kg at 9 mg. It states that gastrointestinal effects and fatigue were mostly mild to moderate.
This 2026 wiki page is unusually candid for a community source: it states that eloralintide is investigational, available only through the sponsor's Phase 3 program, and not for purchase or self-administration, and.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
4 protocol rows on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
2 rows record what blogs, vendor write-ups or forums describe for Eloralintide. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
LY3841136, EX-A9589, AT53786
RLBIFQNAUXZCQB-UHFFFAOYSA-N
20-[[4-[[4-[[5-[[1-[2-[[2-[[4-amino-2-[[4-amino-2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[2-[[2-[[5-amino-2-[[2-[[2-[2-[[20-[(4-amino-4-carboxybutanoyl)amino]-17-(2-amino-2-oxoethyl)-8,14-bis(1-hydroxyethyl)-11-methyl-7,10,13,16,19-pentaoxo-1,3-dithia-6,9,12,15,18-pentazacyclohenicosane-5-carbonyl]amino]propanoylamino]-3-hydroxybutanoyl]amino]acetyl]amino]pentanoyl]amino]-4-methylpentanoyl]amino]propanoylamino]-4-carboxybutanoyl]amino]-2-methyl-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]-methylamino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-6-[[1-[2-[2-[[1-[[1-[[1-[[2-[[1-[[4-amino-1-[[1-[[1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-6-oxohexyl]amino]-1-carboxy-4-oxobutyl]amino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
5 curated references, each with its journal, year and study model, plus 2 community resources reported but not linked.